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Giving

eyesight to the

blind

Penn Vet ophthalmologists’ work in the lab restores
vision to dogs and provides hope to human patients
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ou may remember a dog named Lancelot. In
2001, Dr. Gustavo D. Aguirre, professor of
medical genetics and ophthalmology at Penn Vet,
restored vision to the dog, who was born blind –
and they both made national headlines.
Their next stop? Washington, DC.
“Because of publicity following Lancelot’s recovery of
vision, he was invited to Capitol Hill to meet with members
of Congress,” said Dr. Aguirre. “During the meeting,
Lancelot laid down near the podium and looked carefully at
all the members of the audience who asked questions. Unlike
dogs that are blind but can hear, Lancelot fixed his stare on
the people who asked questions.”
Dr. Aguirre’s goal in traveling to Washington with
Lancelot was to get people to understand and appreciate
the power of and need to continue to develop new therapy
technologies for treating inherited blindness.
Their sojourn to Washington was a success and Dr.
Aguirre’s point was made.
“They all wanted to adopt Lancelot,” said Dr. Aguirre, “so
to me that meant they connected with the idea that this kind
of work is important.”
Serving as lead researcher of the project at the time, Dr.
Aguirre’s work began with Lancelot and a team that included
researchers at Penn’s Scheie Eye Institute and University of
Florida. Their goal was to restore vision to Lancelot and his
littermates that were mixed-breed dogs of Briard origin. This
is the first time that gene therapy was used to successfully
restore vision to any living creature.
By injecting a genetically engineered virus carrying a
healthy copy of the defective gene into the part of the dog’s
retina that contained the retinal pigment epithelium, the cell
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layer that is essential for the proper
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functioning of the light-sensing
cells, Dr. Aguirre and his team
were able to “infect” those cells
with normal gene material. Within
several weeks, cells with the
healthy copy of the gene began to
produce vitamin A in the proper
form needed by the retina that, in
combination with opsin, formed
the visual pigment rhodopsin,
allowing Lancelot to see.
This advance in veterinary medicine offers hope for curing
a similar disease that blinds children at birth or in early childhood – Leber’s congenital amaurosis (LCA), an inherited retinal
disease. And, because of the dog’s successful treatment, human
clinical trials began in 2007 at several centers worldwide,
including the University College of London, the Sheie Eye
Institute and Children’s Hospital of Philadelphia.
But Dr. Aguirre’s and his colleagues’ passion for restoring
sight to the blind using gene therapy didn’t stop with Lancelot.

A SECOND MAJOR BREAKTHROUGH
Working hand-in-hand with researchers at Temple
University, University of Florida and Cornell University,
Dr. András M. Komáromy, assistant professor of
ophthalmology – one of Dr. Aguirre’s colleagues – has
made another major breakthrough in vision recovery with
developing a gene therapy to treat achromatopsia in dogs.
Otherwise known as day blindness, rod monochromacy or
total color blindness, achromatopsia affects the cones in the
eye and makes daytime vision impossible for affected dogs.

Day blindness is rare in humans, affecting approximately one
out of every 30,000 to 50,000, but because it affects the cones
in the eye, Dr. Komáromy, lead author on the study, says it’s
a perfect model to study other diseases affecting the cones, like
macular degeneration in humans. Cones, responsible for day and
color vision, are essential for central visual acuity and most daily
visual activities.
The gene therapy developed by Dr. Komáromy is delivered
directly to the cone cells in the retina and targets mutations of the
CNGB3 gene – a mutation discovered by Dr. Aguirre’s research
group several years ago. The CNGB3 gene codes for an ion
channel that is crucial for normal cone function.
“We administer the virus carrying a normal copy of the
CNGB3 gene underneath the retina,” said Dr. Komáromy. “The
treated part of the retina is temporarily detached following the
injection. The eye is an enclosed organ so you can inject high
doses exactly where you need it.”
“It’s the same gene responsible for 50 – 80 percent of human
achromatopsia,” said Dr. Aguirre. “This work can help researchers
understand how to fight age-related macular degeneration in
people, which is the leading cause of blindness in people over 60.”
“Dogs don’t have a well developed macula as in humans,” said
Dr. Komáromy, “but because achromatopsia is a model cone
disease, it allows us to answer questions for human medicine and
consider important factors like age and allows us to follow up over
a long period of time.”
Dr. Komáromy’s treatment cured younger canines regardless
of the mutation that caused their achromatopsia and was effective
for the 33-month span of the study. The successful restoration
of cone function was documented through a technique called
electroretinography. Researchers also measured the dogs’ ability to
negotiate a short obstacle course in daylight.
“I remember the moment very well during the summer of 2006
when I recorded the recovered cone function for the first time
by electroretinography,” said Dr. Komáromy. “I became very
excited, but I repeated the recordings multiple times and kept
replacing the electrode wires to make sure that I was not dealing
with a technical artifact...the cone signal persisted!”
While younger dogs had tremendous success with this kind of
gene therapy, dogs older than 54 weeks of age had less success.
“Because of the success in younger dogs, it makes sense to keep
going,” said Dr. Komáromy. “We want to develop a treatment for
older dogs.”
The results represent the second successful cone-directed gene
replacement therapy in achromatopsia animal models and the first
outside of mouse models.
The work done by Drs. Komáromy and Aguirre holds promise
for future human clinical trials of cone-directed gene therapy in
achromatopsia and other cone-specific disorders. It holds great
promise to treat dog-specific diseases like the Progressive RodCone Degeneration (PRCD), a hereditary retinal disease that leads
to blindness in dogs between the ages of three to seven years, and
is the most common cause of inherited canine blindness.

More Work in the Lab
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